



# Quantum Sensing in Predictive Health and Early Diagnosis Workshop

**Innovate UK Business Connect**

**Matt Jones - Knowledge Transfer Manager Quantum**  
**Cherie Burnett - Events Manager**

**10<sup>th</sup> October 2024**

**&**

**National Physical Laboratory**

**Alex Jones - Senior Scientist**  
**Ella Cross - Events Manager**



# Session 1

Start	Finish	Activity	Presented by	Institution
09:30	09:40	UK Quantum Technologies Challenge	Dr Callum Stirling	Innovate UK
09:40	09:55	The Government's approach to quantum sensing in healthcare	Faiyaz Amin	Office for Quantum DSIT
09:55	10:10	Quantum Technologies for Life Sciences and Health	Dr Alex Jones	National Physical Laboratory
10:10	10:25		Professor Rachel McKendry	QBioMed Hub
10:25	11:10	UK National Quantum Technologies Programme Activities Discussion	-	-
11:10	11:40	Break	-	-




# Quantum Sensing in Health

## NQTP Activities – UK Quantum Technologies Challenge

Callum Stirling, Innovation Lead – Quantum Technologies  
10<sup>th</sup> October 2024




# What we do



# Quantum Challenge

- Part of NQTP, started in 2018
- SMEs to large corporates, with RTOs & universities
- Products & services onto market
- Catalysing investment



# Quantum Challenge


£263m grants & contracts

£337m of project activity


Approx. 200 collaborating organisations

£693m of investment raised

# Quantum Challenge



- Accelerated investment into growing a competitive UK industrial ecosystem.
- Targets industrialisation, supply chain development, and adoption.
- Continued industrialisation will to be central to National Quantum Strategy.



# Diverse Quantum Ecosystem

- Imaging
- Sensing (magnetic)
- Materials companies (e.g. diamond)
- Components, equipment, systems and services
- New players, incl. start-ups & spin-outs
- “Just add quantum”: established players with existing products, incl. scale-ups and industrial giants
- Other quantum technologies: computing, privacy & security



# Projects

- Quantum technology enabled blood diagnostics for patient centric cancer care & treatment
- Quantum dots attached to cancer cells
- Brain Imaging Using OPM-MEG
- Transforming tissue differentiation via quantum digital tomosynthesis
- Quantum diamond magnetometry for magnetocardiography
- Developing operational healthcare applications using quantum computing techniques


# Find out more...




# Quantum for Life report

- For those in healthcare & life sciences
- Applications of Quantum Technologies
  - Diagnosis & monitoring
  - Optimising healthcare environments
  - Simulating novel drugs
  - Securing patient information
- Capabilities, current & future
- Contact: Matt Jones

Access it here











Department for  
Science, Innovation  
& Technology

# The Government's approach to quantum sensing in healthcare

Faiyaz Amin – Office for Quantum  
(Department for Science Innovation and  
Technology)



# QUANTUM SPANS THREE GROUPS OF TECHNOLOGIES. ALL ARE EXPECTED TO HAVE SIGNIFICANT CROSS-SECTOR IMPACTS OVER THE NEXT DECADE.

Technology	Value	Maturity	Example of UK Case Studies
<b>Quantum computing</b> Solve problems that even the most powerful classical computers cannot	\$450-850 bn in the next 10-15 years*	10+ years until deployed at scale	<p><b>UK company developing quantum algorithms for solving net-zero challenges</b></p> <p>Phasecraft are developing quantum computing applications to <b>tackle optimisation problems in energy grid planning</b>, and <b>model new materials</b></p> 
<b>Quantum communications</b> More secure communications	\$8bn by 2030**	5-10 years until deployed at scale	<p><b>World's first commercial trial of a quantum secured communications network</b></p> <p><b>BT, Toshiba, EY</b> launched a world first quantum-secured network in London connecting customers with <b>secure transmission of valuable data</b></p> 
<b>Quantum sensing</b> Exponentially more powerful sensors	\$5bn by 2030**	5-10 years until deployed at scale	<p><b>Wearable brain scanner with better sensitivity and lower cost</b></p> <p><b>Cerca Magnetics</b> is developing wearable brain scanners that promise a more accurate and accessible <b>diagnosis of neurological conditions</b></p> 


\* Boston Consulting Group, July 2021, "What Happens When 'If' Turns to 'When' in Quantum Computing?"

\*\* McKinsey & Company, December 2021



Department for  
Science, Innovation  
& Technology

# Programme Overview **UK National Quantum Technologies Programme**



# The story so far: £1.1bn National Programme

## Research



- **Centres of excellence:** building regional strengths through the hubs network
- **Unlocking new applications:** targeted research programmes

## Innovation



- **Accelerating commercialisation:** Challenge programme involving 180+ UK companies
- **Driving public sector solutions:** through the Catalyst Fund

## Infrastructure



- **National Quantum Computing Centre:** to accelerate scaling and readiness
- **Testing and assurance:** through the National Physical Laboratory

## Skills



- **Developing, attracting and retaining talent:** through PhDs, fellowships and apprenticeships



# The result: a world-leading ecosystem...



Department for  
Science, Innovation  
& Technology



**World leading research and skills:** 1<sup>st</sup> in Europe and 3<sup>rd</sup> in the world for the quality and impact of quantum research.



**Thriving business community:** 2<sup>nd</sup> for the number of quantum companies (11% of the world's quantum companies)



**High-levels of private investment:** 2<sup>nd</sup> in attracting private equity investment (12% of global private investment)



**Broad capabilities:** Quantum companies spanning computing, communications, sensing, timing, imaging, and the supply chain

## ...with real-world applications



### Reducing industrial emissions

QLM are using lidar to autonomously detect and measure methane emissions.



### Resilient flight navigation

Infleqion completed test flights with quantum-based navigation offering accuracy and resilience to satellite disruption.



### Transforming brain scanning

Cerca's wearable brain scanner trialled in hospitals and is deepening our understanding of brain developments



Department for  
Science, Innovation  
& Technology

# UK National Quantum Strategy



# FOUR GOALS, FIVE MISSIONS



Ensure the UK is home to world-leading quantum science and engineering



Make the UK the go-to place for quantum businesses



Drive the use of quantum technologies in the UK to benefit the economy, society and security



Create a national and international regulatory framework that supports innovation and the ethical use of quantum



By 2035 UK-based quantum computers capable of running 1 trillion operations that provide benefits well in excess of classical supercomputers



By 2035, the UK will have deployed the world's most advanced quantum network at scale, pioneering the future quantum internet.



By 2030, every NHS Trust will benefit from quantum sensing-enabled solutions through early diagnosis and treatment, helping people live healthier, longer lives



By 2030, quantum navigation systems, including clocks, will be deployed on aircraft, providing independent next-generation accuracy for resilience



By 2030, mobile, networked quantum sensors will have unlocked new situational awareness capabilities, exploited across critical infrastructure

# KEY AREAS OF FOCUS



## R&D & Skills

Announcement of new Hubs and Centres for Doctoral Training  
Quantum skills taskforce progressing



## Business Support

Industry engagement on quantum mission delivery



## Adoption

End-user awareness & sector adoption plans



## Regulation

Delivery of recommendations from quantum Regulatory Horizons Council report



## International Partnerships

Delivering key international agreements and activity

## Quantum Missions



Bring together the UK community to innovate and achieve key milestones



Clear and measurable outcomes that tackle major societal challenges



Department for  
Science, Innovation  
& Technology

# Mission 3: Quantum sensing for health



# Mission 3 benefits



Department for  
Science, Innovation  
& Technology

*“By 2030, every NHS Trust will benefit from quantum sensing-enabled solutions, helping those with chronic illness live healthier, longer lives through early diagnosis and treatment.”*



**Addressing major conditions:** Particularly those that are set out in the DHSC Major Conditions Strategy



**Earlier diagnosis and treatment:** From the improved analytical sensitivity of quantum sensors



**Efficiency:** Especially where quantum enhanced imaging or in vitro diagnostic tests can free up hospital capacity



**Personalised medicine:** Improving diversity of options that cater to individual circumstances or biomarkers



## We have heard a heard a range of challenges



Lack of interdisciplinary research and poor understanding of end user requirements



Challenges in the regulatory and adoption pathway



Barriers to spin out and commercialisation



Manufacturing capability and other cross-cutting challenges






# NEXT STEPS

**Mission delivery plan** – We are preparing detailed Mission delivery plans, including road mapping and infrastructure requirements.

- Get in touch with me or via [ofgenquiries@dsit.gov.uk](mailto:ofgenquiries@dsit.gov.uk) to feedback on the shape of mission delivery.

**Spending review** – OfQ & DSIT are involved in the current SR planning process to enable the next phase of the programme.

- Budgets for 25-26 expected by early 2025, with full multiyear plans confirmed by the summer




# The National Physical Laboratory



- **The UK's National Metrology Institute**
  - **Metrology** is the **science of measurement**
- Since 1900 NPL has maintained the nation's primary measurement standards
  - These standards **ensure accuracy and consistency** of measurement across the UK and the world
- **NPL:**
  - Studies measurement **uncertainty**
  - Designs and develops **new measurement technologies**
  - Provides measurement **service**





# Quantum Technologies for Life Sciences and Health

Alex R. Jones

Principal Scientist, Biometrology

National Physical Laboratory

# National Quantum Strategy



- **Building on strong foundations / UK strengths**
  - **Life Sciences** identified as a key user sector / “critical for ... **healthcare**”
- **Enabling quantum technologies**
  - “increase resilience, ..., productivity, and competitiveness across critical sectors [like] **health**...”
- **Goal 3: Driving the adoption of QTech in the UK**
  - “where quantum will deliver the most value for the UK” include **health** and **engineering biology**
  - “drive early adoption in key sectors such as ... **life sciences**”
  - “UK as a world leader in **health** and **life sciences**... **better, cheaper imaging**”
  - “Supporting other UK priority technologies...This includes...**health**...”
  - Accelerate the ... National Quantum Computing Centre SparQ Applications Discovery programme, with specific workstreams ... within the ... **healthcare sector**...”
- **Conclusions**
  - “...benefits and opportunities of QTech are vast and will offer advantages in meeting our... **health**... aims”

# QTech for Life Sciences and Health

**1. Sensing**

**2. Communications**

**3. Computing**



# Mixing Metaphors...

1. Sensing



2. Communications

3. Computing



# NPL Workshop, Bushy House, 18-19 June '24



**Committee:** Prof. Ian Gilmore, Prof. Alexandra Olaya-Castro, Prof. Ivette Fuentes-Guridi, Prof. Sir Peter Knight

**Universities:** UCL, Southampton, Oxford, Nottingham, Edinburgh, York, Bristol, Imperial, Helsinki, Ulm, Cambridge, Glasgow, Dundee





# NPL Workshop, Bushy House, 18-19 June '24



1. Quantum Computing
2. Advanced Technologies for Life Sciences and Health
3. Quantum Metrology
4. Quantum Sensing

# NPL Workshop, Bushy House, 18-19 June '24



1. Quantum Computing
2. Advanced Technologies for Life Sciences and Health
3. Quantum Metrology
4. Quantum Sensing



# Some take-home messages

- **Quantum computing**

- Promise: better scaling, drug outliers, expressivity, “complete” solutions, energy, investment,...
- Challenges: speed, data quality, non-linearity, algorithm development,...
- **“Years of basic research required...” Anon., 2024**

- **Adoption of**

- 1. Regulation
- Challenge

“By 2030, **every NHS Trust** will benefit from **quantum sensing**-enabled solutions, helping those with chronic illness live healthier, longer lives through early diagnosis and treatment.”

- **Metrology**

- Standards (materials, methods), uncertainty (esp. biological), validation,...
- **All vital for successful adoption**

- **Sensing**

- Quantum light; single photon detection; nanodiamond; optically-pumped magnetometry;...
- **Happening now**

# NPL Quantum Programme



Building quantum measurement facilities and infrastructure supporting innovation across the UK, plus research, standards, access, skills.




Projects aligned with the quantum technology hubs



Quantum product development projects led by industry



Quantum technology for fundamental physics



# NPL Life Sciences and Health



PREDICTION  
PREVENTION,  
DETECTION AND  
DIAGNOSTICS



IMPROVED PATIENT  
TREATMENTS



BIOECONOMY



UNDERSTANDING BIOLOGY

MEASUREMENT INFRASTRUCTURE

And addressing national health challenges



# Get 20 days of quantum consultancy, at no charge\*

Could your business benefit from quantum measurement expertise?

The National Physical Laboratory's (NPL) Measurement for Quantum (M4Q) programme provides up to 20 days of specialist support at no charge\*.

**Learn how M4Q can help your business innovation challenges:**


[www.npl.co.uk/measurement-for-quantum](http://www.npl.co.uk/measurement-for-quantum)

\*Eligibility criteria applies. See website for full terms and conditions.



[npl.co.uk](http://npl.co.uk)





# **UK Quantum Biomedical Sensing Research Hub**

**Professor Rachel McKendry**

London Centre for Nanotechnology  
and Division of Medicine UCL

**Quantum Sensing in Predictive Health and Early  
Diagnosis Workshop**

10<sup>th</sup> October 2024



# 1) Introduction: Prof. Rachel McKendry



Professor Biomedicine and Nanotechnology UCL  
Prev. BSc and PhD Chemistry Durham Cambridge  
Junior Research Fellow Cambridge, IBM Zurich



London Centre for Nanotechnology  
UCL, Imperial & Kings College



Division of Medicine UCL

[Email: r.a.mckendry@ucl.ac.uk](mailto:r.a.mckendry@ucl.ac.uk)

## Brief Introduction: McKendry group@UCL



£20M i-sense EPSRC IRC in Early Warning Systems for Infectious Diseases and AMR (2023-24)

£5M EPSRC Digital Health Hub for AMR: <https://www.digitalamr.org>

£24M Q-BIOMED Hub (starts Dec 2024): <https://www.qbiomed.org.uk>

Collaborations; academic, clinical, public health and industry partners, including UCL, Imperial, Oxford, Cambridge, UCLA, Johns Hopkins, the NHS, UCLH, GOSH, Public Health England/ UK Health Security Agency, Africa Health Research Institute, Uganda Virus Research Institute, CESHAR Zimbabwe, icddr,b, Google and Microsoft

**Vancomycin**  
**Oritavancin**

**nature nanotechnology** **ARTICLES**  
PUBLISHED ONLINE: 2 MARCH 2014 | DOI: 10.1038/NNANO.2014.33

**Surface-stress sensors for rapid and ultrasensitive detection of active free drugs in human serum**

Joseph W. Ndieyira<sup>1,2\*</sup>, Natascha Kappeler<sup>1</sup>, Stephen Logan<sup>1</sup>, Matthew A. Cooper<sup>1</sup>, Chris Abell<sup>1</sup>, Rachel A. McKendry<sup>1\*</sup> and Gabriel Aeppli<sup>1</sup>

**Biomedicine**

**nature medicine** **LETTERS**  
<https://doi.org/10.1038/nm41591-021-01384-9>  
Check for updates

**Deep learning of HIV field-based rapid tests**

Valérian Turbé<sup>1,2\*</sup>, Carina Herbst<sup>1</sup>, Thobeka Mngomezulu<sup>1</sup>, Sepehr Meshkinfamard<sup>1</sup>, Nondumiso Dlamini<sup>1</sup>, Themani Mhlongo<sup>1</sup>, Theresa Smit<sup>1</sup>, Valeria Cherepanova<sup>1</sup>, Koki Shimada<sup>1</sup>, Jobie Budd<sup>1,4</sup>, Nestor Arsenov<sup>1</sup>, Steven Gray<sup>1,5</sup>, Deenan Pillay<sup>1,2,4</sup>, Kobus Herbst<sup>1,2,5,6</sup>, Maryam Shahmanesh<sup>1,2,4,5,6</sup> and Rachel A. McKendry<sup>1,4,5,6</sup>

**Global health**

**Article**  
**Spin-enhanced nanodiamond biosensing for ultrasensitive diagnostics** **nature**  
<https://doi.org/10.1038/n41586-020-2917-1>  
Received: 24 May 2019

Benjamin S. Miller<sup>1,2,3</sup>, Léonard Beziings<sup>1</sup>, Harriet D. Gliddon<sup>1</sup>, Da Huang<sup>1</sup>, Gavin Dold<sup>1,2</sup>, Eleanor R. Gray<sup>1</sup>, Judith Heaney<sup>1</sup>, Peter J. Dobson<sup>1</sup>, Eleni Nantoulis<sup>1</sup>, John J. L. Morton<sup>1,2</sup> & Rachel A. McKendry<sup>1,2,3</sup>


**Nano/quantum**

**nature medicine** **REVIEW ARTICLE**  
<https://doi.org/10.1038/n41591-020-1011-4>  
Check for updates

**Digital technologies in the public-health response to COVID-19**

Jobie Budd<sup>1,2</sup>, Benjamin S. Miller<sup>1</sup>, Erin M. Manning<sup>1</sup>, Vasileios Lamos<sup>1,3</sup>, Mengdie Zhuang<sup>1</sup>, Michael Edelstein<sup>1</sup>, Geraint Rees<sup>1,4</sup>, Vincent C. Emery<sup>1,5</sup>, Molly M. Stevens<sup>1,6</sup>, Neil Keegan<sup>1</sup>, Michael J. Short<sup>1,6</sup>, Deenan Pillay<sup>1,7</sup>, Ed Manley<sup>1,8</sup>, Ingemar J. Cox<sup>1,9</sup>, David Heymann<sup>1</sup>, Anne M. Johnson<sup>1,6</sup> and Rachel A. McKendry<sup>1,2,3,10</sup>

**Digital health**



## Policy Roles:

UK National Quantum Technologies Programme  
Quantum Mission for Health Working Group

WHO Public Health Research Agenda for Influenza 2024


100 Days Mission Scientific and Technical Advisory Board  
Diagnostic Implementation Report

Chaired Advisory Group to UKHSA NBN Programme

Co-lead Digital Health Theme of Topol Review

Cross council Steering Committee on AMR

# Quantum for health



New wave quantum technologies  
powered by ability to access individual quantum systems  
– *such as single atoms, photons and other coherent effects.*

# The future of healthcare

**EARLY DIAGNOSIS & PRECISION MEDICINE**

**COMMUNITY CARE**

**PREVENTION**




Department  
of Health &  
Social Care

Independent report

## Summary letter from Lord Darzi to the Secretary of State for Health and Social Care

Updated 25 September 2024



“I would love to see a world in my lifetime in which no antibiotic could be prescribed without a diagnostic test and that diagnostic test has to be quick and available”

**Lord Darzi, Executive Chair of the Fleming Initiative September 2024**



NHS 75

CELEBRATING  
**75 YEARS**  
of the **NHS**

#NHS75

## The King's Fund >

“Diagnostics are tests or procedures used to identify a person’s disease or condition.


Finding out what is wrong with someone is vital to treating them

**more than 85% of people seeking NHS care require diagnostics.**

Prompt diagnosis can save lives  
**Early diagnosis of cancer substantially improves survival rates, for example saves time and money, and avoids worsening patient outcomes.**

Diagnostics also have an important role to play in **preventive health** by improving early detection of illness”

Optically pumped magnetometers (OPMs)



Diamond with NV centres



## Emerging new quantum sensors


Quantum sensors have the potential for many advantages over classical sensors:

- Greater sensitivity – orders of magnitude
- Size, spatial and temporal resolution
- Complex backgrounds
- Lighter and more portable
- Energy-efficient
- Cost-effective

nature reviews physics

<https://doi.org/10.1038/s42254-023-00558-3>

Review article

 Check for updates

### Quantum sensors for biomedical applications

Nabeel Aslam<sup>1,2,3</sup>, Hengyun Zhou<sup>1</sup>, Elana K. Urbach<sup>1</sup>, Matthew J. Turner<sup>4,5</sup>, Ronald L. Walsworth<sup>4,5,6</sup>, Mikhail D. Lukin<sup>1</sup> & Hongkun Park<sup>1,2</sup>✉



# Transforming the world with quantum technology



UK NATIONAL  
QUANTUM  
TECHNOLOGIES  
PROGRAMME



## Our achievements so far

470+

PhD candidates supported



14

Fellowships funded, with more due in 2022



£147m

awarded to the Industrial Strategy Challenge Fund

£93m

invested in the National Quantum Computing Centre

£214m

invested in Quantum Technology Hubs

£40m

of Quantum Technology for Fundamental Physics projects funded


120+

Hub industrial partners



49

Start-ups generated






Quantum Computing and Simulations Hub  
(Oxford)



Quantum Communications Hub  
(York)



**Current  
Quantum  
Technology  
Hubs**




Quantum Sensors and Timing Hub  
(Birmingham)



Quantum Enhanced Imaging  
(Glasgow)


Healthcare, energy, transport, civil engineering,  
manufacturing, defence, gravity sensors for surveying,  
quantum clocks for global navigation satellite systems



# Q-BIOMED

THE UK QUANTUM BIOMEDICAL  
SENSING RESEARCH HUB

*Delivering the quantum-enabled future of  
early disease diagnosis and treatment*



Other partners: 17 industry,  
government, regulators, standards

Call opened January 2023; July 2024 £24M funding announced (2024-29)

Policy paper

# National Quantum Strategy Missions

Updated 14 December 2023

Mission 1 Quantum Computers


Mission 2 Quantum Networks

**Mission 3 Quantum Sensing for Health**

By 2030, every NHS Trust will benefit from quantum sensing-enabled solutions, helping those with chronic illness live healthier, longer lives through early diagnosis and treatment.

Mission 4 Quantum Navigation Systems

Mission 5 Networked quantum Sensors.



# Quantum Sciences



# Biomedicine



## Our management team:



McKendry  
Chemistry



Atature  
Physics



Morton  
Elect Eng



Stevens  
Biomed Eng



Knowles  
Physics



Sebire  
Pediatrics



Shipley  
Med Eng



Pankhurst  
Med Phys



Bonato  
Physics



Newton  
Physics



Williams  
Engineering



Lambiase  
Cardiology



Nastouli  
Infection



Munoz  
Cancer



Shahmanesh  
Infection




Hughes  
Social Science



# Q-BIOMED

THE UK QUANTUM BIOMEDICAL SENSING RESEARCH HUB





# Clinical partners





Selection of industry partners (17 in total):




**PHILIPS**

**endomag<sup>+</sup>**

**ABHI**

**elementsix™**  
DE BEERS GROUP



**AstraZeneca**

**QDTI**



Aim to grow new collaborations to create an innovation ecosystem

# WP1: Systems-level Perspective of User Needs



## Professor Becky Shipley OBE

Professor of Healthcare Engineering, UCL; Chief Research Officer & Director of Academic Health Science Centre UCL Partners






## Professor Neil Sebire

Professor of Pathology and Chief Research Information Officer (CRIO) Great Ormond Street Hospital, Previous HDR UK Chief Clinical Data Officer

**Round tables:** clinical, patients, charities, industry, government, regulators, public, international

Use cases: Screening, early diagnosis, stratification, prognosis, response to treatment etc

Inequalities and responsible innovation




# WP2: Core Research Programme

## Biomedical Imaging and Physiology


### ATRIAL FIBRILLATION

Impulses have chaotic, random pathways in atria





**NIHR** | Barts Biomedical  
Research Centre

## In-Vitro Diagnostics



## Interventions Surgery & Treatment



Quantum biosensing for biomedical research

# Flagship 1: Biomedical Imaging MASER enhanced MRI



Exploring new imaging paradigms and faster scans to help to cut waiting times and ease pressure on the NHS




MASERs (microwave amplification by stimulated emission of radiation)

# Can we harness quantum sensors to detect the earliest stages of Alzheimer's disease?



UK Dementia  
Research Institute



**Estimated 900,000 people with Alzheimer's Disease in the UK**

**Aim** to detect subtle changes in brain circuitry, with a focus on OPM-MEGs as well as NVs.

**Impact:** functional pre-symptomatic biomarker for access emerging treatments (e.g., lecanemab) to slow cognitive decline prior to extensive neuronal loss.



# Flagship 2: Quantum-enhanced IVD and rapid tests

Exploring applications spanning infections, AMR, cancer, cardiovascular disease



Article

## Spin-enhanced nanodiamond biosensing for ultrasensitive diagnostics

<https://doi.org/10.1038/s41586-020-2917-1>

Received: 24 May 2019

Accepted: 16 September 2020




Benjamin S. Miller<sup>1,2,3</sup>, Léonard Beziuge<sup>1</sup>, Harriet D. Gliddon<sup>1</sup>, Da Huang<sup>1</sup>, Gavin Dold<sup>1,3</sup>, Eleanor R. Gray<sup>1</sup>, Judith Heaney<sup>1</sup>, Peter J. Dobson<sup>2</sup>, Eleni Nastouli<sup>4</sup>, John J. L. Morton<sup>1,3</sup> & Rachel A. McKendry<sup>1,2,5</sup>

**nature**  
International weekly journal of science


*Nature* **587**, 588 (2020)

100,000 fold more sensitive than gold nanoparticle fundamental sensitivity improvement

10<sup>3</sup>-10<sup>4</sup> fold with clinical samples



## Flagship 3: Quantum Enhanced Interventional Tools




A magnetic marker liquid injected into people with invasive breast cancer will help surgeons discover if the cancer has spread, after the technology was recommended in draft NICE guidance.

[www.NICE.org.uk](http://www.NICE.org.uk)

**1000+ hospitals, 45+ countries. 400,000+ women** will have now accessed more precise and less invasive breast cancer treatment





## Flagship 4: Quantum for Biomedical Research

Multimodal quantum sensing in living systems  
(Temperature, electron spins, nuclear spins, charge, micro rheology,  
magnetic fields, ions (Reactive oxygen species))

Single cell and single molecule lengths scales

Intracellular dynamics linked to cancer, neurodegenerative diseases and viral replication.



CANCER  
RESEARCH  
UK

Addenbrooke's **NHS**  
NHS Trust



UNIVERSITY OF  
CAMBRIDGE

UNIVERSITY OF  
OXFORD



HERIOT  
WATT  
UNIVERSITY





## WP3 Accelerating Technology Impact

IP, patents, licensing, new industry partners, joint ventures, spinouts

## WP4 Future Leaders Programme

## WP5 Impact and Engagement

- National and international centre of excellence
- Working with NQTP, Quantum Hubs and NHS
- Growing innovation ecosystem with industry
- Giving balanced information to policy makers and the public

# Growing international networks of excellence



*Delivering the quantum-enabled future of early disease diagnosis and treatment*




## Acknowledgements

Our Hub will start on 1<sup>st</sup> December Please go to [www.q.biomed.org.uk](http://www.q.biomed.org.uk) to sign up to our newsletter

We are always open to new collaborations



31 Co-Investigators and 40+ partners




# UK National Quantum Technologies Programme Activities Discussion

- This discussion aims to obtain general opinions of the quantum technology pipeline within healthcare based on the strategy and relevant opportunities. Examples include; committed strategy mission, funding and identified areas of interest. The second part of this discussion is to compare current/ past technology adoption and strategy (photonics, AI) and the successes/ problems these had.

## Session 2 – Chaired by Jonathan Legh-Smith

Start	Finish	Activity	Presented by	Institution
11:40	11:55	Monitoring Metastasis	Dr Manfredi San Germano	Beyond Blood Diagnostics
11:55	12:10	Digistain mid-IR Cancer Diagnosis; Saving Lives with Quantum Entanglement	Dr Nathan Gemmell	Digistain
12:10	12:25	Robust Quantum Sensing	Dr Joe Smith	RobQuant
12:25	13:10	Quantum Sensing and Imaging Applications Discussion	-	-
13:10	14:20	Lunch	-	-




**Beyond Blood  
Diagnostics**

**Monitoring  
Metastasis**







# Problem




# Problem




Quantum Sensing?

# Label-Free CTC Detection Using Autofluorescence




# Label-Free CTC Detection Using Autofluorescence



Note: This illustration conceptually represents label-free cell detection via autofluorescence. The specific excitation wavelengths and emission intensities are backed by data from existing literature.


# Label-Free CTC Detection Using Autofluorescence




Note: This illustration conceptually represents label-free cell detection via autofluorescence. The specific excitation wavelengths and emission intensities are backed by data from existing literature.

# Superpower

## Technology info






**PATENT PENDING**



### How our tech works


- + Cells shine at different intensities
- + Our hardware design enables us to align cells individually in channels to detect the light emitted by each cell
- + Our AI processes the signal generated by the hardware, improving constantly





# Wider Benefits To Healthcare


# Autofluorescence




# Antibody Drug Conjugate (ADC) Treatment Guidance

1. Circulating Tumour Cells (CTCs) with Unique Antigen Profiles

CTC 1










CTC 2



Cellular level (CTC)

**Legend**


	CTC Surface		Antigen 2 (Eg: EpCam variant 2)
	Antigen 1 (Eg: EpCam Variant 1)		Fluorescent particle designed to bind only to Antigen 2
	Fluorescent particle designed to bind only to Antigen 1		Specific ADC targeting Antigen 2
	Specific ADC targeting Antigen 1		

# Antibody Drug Conjugate (ADC) Treatment Guidance


1. Circulating Tumour Cells (CTCs) with Unique Antigen Profiles

2. Targeted Binding of Fluorescent Nanomaterials to Antigens

CTC 1



CTC 2



Cellular level (CTC)










Cellular level (CTC)

BBD + Partner



**Legend**

	CTC Surface		Antigen 1 (Eg: EpCam Variant 1)		Antigen 2 (Eg: EpCam variant 2)
	Fluorescent particle designed to bind only to Antigen 1		Fluorescent particle designed to bind only to Antigen 2		Specific ADC targeting Antigen 1
			Specific ADC targeting Antigen 2		


# Antibody Drug Conjugate (ADC) Treatment Guidance

1. Circulating Tumour Cells (CTCs) with Unique Antigen Profiles


2. Targeted Binding of Fluorescent Nanomaterials to Antigens

3. Personalized Antibody-Drug Conjugate (ADC) Guidance Based on Antigen Expression

CTC 1



CTC 2



Cellular level (CTC)

Cellular level (CTC)

Tumour level

BBD + Partner




Clinical Decisions

**Legend**




- CTC Surface
- Antigen 1 (Eg: EpCam Variant 1)
- Antigen 2 (Eg: EpCam variant 2)
- Fluorescent particle designed to bind only to Antigen 1
- Fluorescent particle designed to bind only to Antigen 2
- Specific ADC targeting Antigen 1
- Specific ADC targeting Antigen 2

Stage of Prototype?

# August 2022 - Rare Cell Count (CTCs) - TRL 2




## August 2024 - Rare Cell Count (CTCs) - TRL 4






# Circulating Cancer Cell Detection

## Technology Potential



CTCs



White Blood Count



Platelets



Red Blood Count

# Partners and Support




Innovate  
UK



Blackpool Teaching Hospitals  
NHS Foundation Trust







**IMPERIAL**

# Digistain mid-IR Cancer Diagnosis; Saving Lives with

## Quantum Entanglement

Nathan Gemmell, Rupert Oulton, Chris Phillips

Physics Dept., Imperial College London.

**EPSRC**

 THE ROYAL  
SOCIETY

**NHS**  
National Institute for  
Health Research










# IMPERIAL

## Taking the Guesswork out of Cancer Diagnosis.

- \* Uncertainty in H+E diagnosis generates ~60% of unnecessary Chemo.
- \* We measure increase in DNA accompanying Breast Cancer objectively, using mid-IR spectroscopy.
- \* A YCombinator Company, with multiple successful trials, grants and prizes.
- \* IP portfolio, and Regulatory approval for US and UK.



Hemmel Amrania PhD



# IMPERIAL

## Digistain IR-based Breast Cancer diagnosis technology, an N = 801 validation study

Charles Coombes<sup>1</sup> · Christina Angelou<sup>1</sup> · Zamzam Al Khalili<sup>1</sup> · William Hart<sup>1</sup> · Darius Francescatti<sup>2</sup> · Nicholas Wright<sup>3</sup> · Ian Ellis<sup>4</sup> , Andrew Green<sup>4</sup> , Emad Rakha<sup>4</sup> , Hemmel Amrania<sup>1</sup> , Carlo Palmieri<sup>5</sup> and Chris C. Phillips<sup>1</sup>

*1 Imperial College London, South Kensington Campus, London SW7 2AZ, UK.*

*2 Rush Medical College, Chicago, USA.*

*3 Barts Cancer Institute, London, UK.*

*4 Nottingham University Hospital, Nottingham, UK*

*5 University of Liverpool, Liverpool, UK.*



Royal Society  
Innovation  
Award  
Presented By  
HRH  
Business  
Innovation  
Award  
2022  
Institute of  
Physics  
Innovation Award



Imperial College  
President's Award  
For  
Outstanding  
Research  
CANCER  
RESEARCH  
UK  
Cancer  
Research UK  
Pioneer Award

# Code Dx





# **\*\*"Budget Impact Analysis"** IMPERIAL

## **Commissioned by Innovate UK (on SMART Award)**

"The results indicate that Digistain® can lead to statistically significant cumulative savings of an average of GBP 286.7 million for an LN0 intermediate-risk patient population once rolled out as a substitute for Oncotype DX® (Table 1 , Scenario 2 – LN0 patients). "

"The secondary outcome modelled as the impact of Digistain® on health outcomes as quantified by life years saved (LYS) shows the biggest impact for a LN1-3 patient population once rolled out as a substitute to the currently used PREDICT tool for risk stratification (Table 2 , Scenario 2 – LN1-3 patients), where the model predicts a statistically significant result of an average of 1266 Life Years Saved. "

**\*Figures only for UK and Breast. Much larger worldwide/other Cancers**







Health Enterprise East Ltd  
St John's Innovation Centre  
Cowley Road, Cambridge  
CB4 0WS

+44 (0) 1223 422422  
enquiries@healthtechenterprise.co.uk  
[www.healthtechenterprise.co.uk](http://www.healthtechenterprise.co.uk)



# IMPERIAL

## The “300K Thermal Background” problem.



Ever present 300K Blackbody radiation fluctuates with a  $1/f$  intensity distribution and can't be removed.





# IMPERIAL

## The “300K Thermal Background” problem.

Thermal IR ( $\lambda \sim 10\mu\text{m}$ ) beckons for

- \*Undetectable ranging
- \*Chemical Imaging
- \*Remote sensing

BUT... it adds Poisson noise

Aka “BLIP” Limits to IR detection sensitivity

AND... it Fluctuates.

300K  
Black Body




FIG. 6-59. Low-resolution solar spectrum from 1 to 24  $\mu$ .




# IMPERIAL

## Quantum Imaging with Undetected Photons

Uses TWO identical entangled photon pair sources (Non-Linear Crystals, NLCs).

"Signal" beams are overlapped onto camera: you can't tell which NLC source they came from.

Interference is only seen as long as you can't know which NLC the photons came from => stops if you block the "Idler".



Zeilinger's group Lemos et al. "Quantum Imaging with undetected Photons" Nature 512, 409-413, (2014).



# “EntangleCam” Mk 1




# IMPERIAL



**QUANTIC**  
The UK Quantum Technology Hub  
in Quantum Enhanced Imaging








UK NATIONAL  
**QUANTUM  
TECHNOLOGIES  
PROGRAMME**



# “EntangleCam” Mk 2

# IMPERIAL

Emma Pearce,  
 \* Nathan R. Gemmell,  
 Jefferson Flórez, Jiaye  
 Ding, Rupert F. Oulton,  
 Alex S. Clark, and Chris C.  
 Phillips “Practical  
 quantum imaging with  
 undetected photons”  
**Optics Continuum**. Vol.  
 2, Issue 11, pp. 2386-2397  
 (2023)





## “EntangleCam” Mk 2



# IMPERIAL

Emma Pearce,  
\* Nathan R. Gemmell,  
Jefferson Flórez, Jiaye  
Ding, Rupert F. Oulton,  
Alex S. Clark, and Chris C.  
Phillips “Practical  
quantum imaging with  
undetected photons”  
**Optics Continuum**. Vol.  
2, Issue 11, pp. 2386-2397  
(2023)








**IMPERIAL**

**Thermal background left behind...**

PHYSICAL REVIEW A **108**, 032613 (2023)

---

**Eliminating thermal infrared background noise by imaging with undetected photons**

Yue Ma , Nathan Gemmell, Emma Pearce , Rupert Oulton, and Chris Phillips 

*Blackett Laboratory, Imperial College London, London SW7 2AZ, United Kingdom*



(Received 15 March 2023; accepted 18 July 2023; published 21 September 2023)





# IMPERIAL

London, Glasgow, San Francisco, Munich...





Acton...

IMPERIAL








# IMPERIAL

To be “realigned” by HMG security...





## Houses of Parliament

# IMPERIAL

**Andrew Griffith,**  
Minister of State, DSIT.  
( HoC Nov 2023)





# IMPERIAL

## The Future...

“In the event that EntangleCam performs in accordance with the assumptions made in this report, there is the opportunity for the technology to compete for some of the share within the £1bn imaging and microscopy segment of the anatomic pathology market and/or the £15bn biomarker industry. More specifically, improvements to the current Digistain platform could lead to >£100m of incremental growth over the coming 6-year period.”

Independent report by Beacon Advisors (Commissioned through EPSRC)



## National quantum strategy

### **Mission 1**

By 2035, there will be accessible, UK-based quantum computers capable of running 1 trillion operations and supporting applications that provide benefits well in excess of classical supercomputers across key sectors of the economy.

### **Mission 2**

By 2035, the UK will have deployed the world's most advanced quantum network at scale, pioneering the future quantum internet.

### **Mission 3**

**By 2030, every NHS Trust will benefit from quantum sensing-enabled solutions, helping those with chronic illness live healthier, longer lives through early diagnosis and treatment.**

### **Mission 4**

By 2030, quantum navigation systems, including clocks, will be deployed on aircraft, providing next-generation accuracy for resilience that is independent of satellite signals.

### **Mission 5**

By 2030, mobile, networked quantum sensors will have unlocked new situational awareness capabilities, exploited across critical infrastructure in the transport, telecoms, energy, and defence sectors.



# IMPERIAL

## National quantum strategy

Chancellors Autumn Statement 2023.....

**Cancer detection:** By 2030, new quantum imaging technologies for breast cancer detection will be in use across hospitals in the UK, significantly reducing the need for unnecessary chemotherapy. Hospital trials across a wide range of cancer types will also be well advanced.

<https://www.gov.uk/government/publications/national-quantum-strategy/national-quantum-strategy-missions>





# IMPERIAL

## Many thanks to...

- **George Greaves<sup>1</sup>, Hemmel Amrania<sup>1</sup>, Zamzam Al-khalili<sup>1</sup>, Emma Pearce,<sup>1,\*</sup> Nathan Gemmell,<sup>1</sup> Jefferson Flórez,<sup>1</sup> Jiaye Ding,<sup>1</sup> Rupert Oulton, Alex Clark, Yue Ma.**
- **William R Otto,<sup>2</sup> Nicholas A. Wright,<sup>2,3</sup>**
- **Charles Coombes<sup>4</sup>, Sami Shousa<sup>4</sup>, Laura Woodley<sup>4</sup> and Charlotte Wihelm-Benarzi<sup>4</sup>, Matt Fuchter<sup>5</sup>, Alex Porter<sup>6</sup>, Eric Aboyage<sup>4</sup>,**
- **Leanne Allison<sup>7</sup>, Perdro Machado<sup>7</sup>, Corinne Morfill<sup>8</sup> and Roland Fleck<sup>7,8</sup>**
- *<sup>1</sup> Experimental Solid State Group, Physics Dept., Imperial College, London, SW7 2AZ, UK*
- *<sup>2</sup> Histopathology Laboratory, Cancer Research UK, London Research Institute, 44, Lincoln's Inn Fields, London, WC2A 3LY.*
- *<sup>3</sup> Centre for Digestive Diseases, Barts and the London School of Medicine and Dentistry, Queen Mary University of London*
- *<sup>4</sup> Department of Cancer and Surgery, Faculty of Medicine, ICTEM, Room 145, Du Cane Road  
London W12 0NN.*
- *<sup>5</sup> Dept Chemistry, Imperial College, London, SW7 2AZ, UK.*
- *<sup>6</sup> Dept Materials, Imperial College, London, SW7 2AZ, UK*
- *<sup>7</sup> Centre for Ultrastructural Imaging, Kings College London, SE1 1UL, United Kingdom*
- *<sup>8</sup> Randall Centre for Cell and Molecular Biophysics, Kings College London, SE1 1YR, United Kingdom*

The logo for EPSRC (Engineering and Physical Sciences Research Council), featuring the letters 'EPSRC' in a bold, purple, serif font, with two horizontal teal lines above and below the text.


**EPSRC**



Further.

**IMPERIAL**










# ROBQUANT

Robust quantum sensing

**Dr Joe Smith**  
**Chief Scientist**


Quantum Sensing in Predictive Health  
and Early Diagnosis Workshop,  
InnovateUK, October 2024



# Problem Statement

1-in-six in the UK have a known neurological condition such as

- Dementia
- Strokes
- Epilepsy



# Solution: Early diagnosis (Predictive health)




Joe Smith

[joe@robquant.com](mailto:joe@robquant.com)

# Barriers

Low cost




Deployable

Sensitive

## Current brain imaging: fMRI



**Low cost**




**Deployable**

**Sensitive**

## Current brain imaging: fNIRS




Low cost



Deployable

Sensitive

# What about quantum sensors?



Quantum sensors can be used to measure a wide range of physical quantities with high sensitivity and precision.

# Quantum sensing in healthcare: Magnetoencephalography

## Superconducting Quantum Interference Device

- Established 1960s
- In 10 centres UK-wide
- Despite promise: Too bulky, too expensive (including to maintain)

## Atom vapour cells from CercaMagnetics and quSPIN


(£ 1.7 M Feb 2023). In ~5 hospital trials across UK, Canada, US.



## Current brain imaging: MEG



**Low cost**




**Deployable**


**Sensitive**

# RobQuant's prototype sensor after > 10 years research at MIT and Bristol


Weng et al. ACS Photonics 10 (9), 3302–3309 2023



Weng et al. *under review*  
arXiv:2404.04075




Smith et al. Advanced Science 11 (2), 2304449 2024



Pending patents

- GB2307741.5
- GB2404816.7



Joe Smith


[joe@robquant.com](mailto:joe@robquant.com)



# ROBQUANT

## Our product:

- Non-invasive magnetic scanning
- Small and light-weight
- Wearable
- Does not require special room/lab
- Volume manufacturable




Joe Smith

[joe@robquant.com](mailto:joe@robquant.com)



# ROBQUANT



10  $\mu\text{m}$   
(1/10 human hair width)

Low cost



Deployable

Sensitive

Joe Smith

[joe@robquant.com](mailto:joe@robquant.com)

# RobQuant traction



- First market sales
- Grant income
- SETsquared incubated
- Growing team



Joe Smith

[joe@robquant.com](mailto:joe@robquant.com)



# What's next?



- Initial cost to manufacture high. More units → lower cost
- Volume manufacture requires volume uptake: healthcare market tough!
- **We're here for conversations!**




# Quantum Sensing and Imaging Applications Discussion

- This second session will address additional areas where Quantum Sensing and Imaging would be useful and who else could use this technology. For example, Cerca Magnetics who use Optically pumped magnetometers for brain MEG based imaging, can be applied to sense magnetic fields from other parts of the body, such as the nervous system. Information can also be drawn from the what you have seen and the Innovate UK Quantum for Life Report. This session will also ask about what competing technologies do you know about and wider conversations about their benefits.



# Session 3 – Chaired by Amy Romaniuk

Start	Finish	Activity	Presented by	Institution
14:20	14:35	Saving Schrödinger's cat Glioma Radiogenomics for non-invasive genetic prediction of adult glioma	Dr Akshaykumar Kamble	Imaging Beyond
14:35	14:50	Design and development of medical devices – key issues to watch out for	Dr Tom Harvey	CPI
14:50	15:05	The Voice of Healthtech	Nishan Sunthares	ABHI
15:05	15:15	Product Development With Clinical Input	Dr Christin Henein and Dr Ben Hunt	UCL and Siloton
15:15	15:50	Health Infrastructure and Technology Translation Discussion	-	-
15:50	16:00	Quantum sensing: Revolutionising Predictive Health & Early Diagnosis - Final Comments	Professor Melissa Mather	Government Office for Science   University of Nottingham



# Design and development of medical devices – key issues to watch out for

**Dr Tom Harvey**

Chief Technologist, Healthtech



**We help companies to  
develop, prove, scale-up  
and commercialise new  
products and processes**



Let's innovate together  
[www.uk-cpi.com](http://www.uk-cpi.com)



# Focus areas



## Medical devices

Fast-tracking MedTech, with **multi-disciplinary teams** supporting across technology verification, concept design and rapid prototyping to pre-clinical scale up process development


We specialise in **new materials**, **novel form factors** and the challenges of **scale up**



## In-vitro diagnostics

Accelerating the development of specific, reproducible and affordable diagnostic solutions

CPI can support from synthesis, characterisation and scale up of **novel reagents** through to development of **new sensors**, assays, **custom readers** and **digital connectivity**



## Wearable health

Making **next generation devices** lighter, smarter, stretchable and more **functional**, with integrated sensors and seamless data transfer

We specialise in additive manufacturing, anatomical phantoms, and converting traditional electronics to flexible hybrid circuits




## Internet of medical things


Developing **smart technologies** that **defy boundaries** to connect medical devices and bring digital HealthTech solutions to patients.

We have an **'end to end' offering** across sensor development, electrical, mechanical, firmware, and software including NFC, RFID, Bluetooth and 5G communication

# Example: Quantum sensing for End-of-Line Battery Testing. Innovate UK Project Number: 42186




Product concept



Mechanical design



OPM module



Electronics & Firmware

Project partners: AMTE Power Ltd, CPI, Kelvin Nano Technology Ltd, University of Strathclyde, University of Sussex, Alter Technology Ltd, CDO2 Ltd, CSC, CST Ltd, Magnetic Shields Ltd.

Duration: August 2020 to May 2024.

Let's innovate together  
[www.uk-cpi.com](http://www.uk-cpi.com)



# HealthTech Regulatory and Innovation programme (HealthTRIP)

**When:** February 2022 to March 2023

**How:** It was delivered by **CPI**, in partnership with ABHI and Cambridge Design Partnership, and funded by Innovate UK.

**What:** It provided a wide package of support to the UK HealthTech industry to help in a changing regulatory environment

**Why:** Meeting medical device and IVD regulations remains a massive challenge for the industry as regulation remains prohibitively complex for SMEs without in-house expertise.

Products continue to be **withdrawn**, and innovative new devices **fail** to navigate to the market.

£7.3 million  
funding  
awarded

277 UK SMEs  
supported

An Action  
Plan:  
Driving  
Growth of  
the UK  
**Digital  
Health  
Industry**

Challenges and  
opportunities for  
the UK  
**HealthTech  
industry**

A strategic  
technology  
roadmap  
for the UK  
**IVD  
industry**


Regulatory  
training was  
accessed  
over **12,000**  
times.

Challenges and  
Opportunities for UK  
HealthTech  
**Manufacturing  
Scale-up**

Let's innovate together  
[www.uk-cpi.com](http://www.uk-cpi.com)




# HealthTRIP - outputs



CHALLENGES and OPPORTUNITIES for the UK HEALTHTECH INDUSTRY

An output from the HEALTH TECHNOLOGY REGULATORY and INNOVATION PROGRAMME


[www.uk-cpi.com/HTRIP](http://www.uk-cpi.com/HTRIP)



A STRATEGIC TECHNOLOGY ROADMAP FOR THE UK IVD INDUSTRY

An output from the HEALTH TECHNOLOGY REGULATORY and INNOVATION PROGRAMME

[www.uk-cpi.com/IVD-roadmap](http://www.uk-cpi.com/IVD-roadmap)



CHALLENGES and OPPORTUNITIES for UK HEALTHTECH MANUFACTURING SCALE UP

An output from the HEALTH TECHNOLOGY REGULATORY and INNOVATION PROGRAMME

[www.uk-cpi.com/healthtech-scale-up-report](http://www.uk-cpi.com/healthtech-scale-up-report)



AN ACTION PLAN: DRIVING GROWTH of the UK DIGITAL HEALTH INDUSTRY

An output from the HEALTH TECHNOLOGY REGULATORY and INNOVATION PROGRAMME

[www.uk-cpi.com/healthtech-digital-health-report](http://www.uk-cpi.com/healthtech-digital-health-report)



# Regulatory challenges – general findings

SMEs find regulations confusing

- Especially with all the recent flux

Some (early) SMEs struggle even with ‘simple’ regulatory concepts

- Demand for a clear “Regulatory Roadmap”


Most common comments and questions:

- “What do I do, when?”
- “What should I ask, and when?”

General CPI SME asks:

- “How long will regulatory take me?”
- “How much will it cost me?”

# Accelerated Access Collaborative (AAC) Health Technology Pathway: Navigation Tool for Innovators in England



Ref: <https://www.england.nhs.uk/aac/wp-content/uploads/sites/50/2023/04/aac005a-health-technology-pathway-map.pdf>

Let's innovate together  
www.uk-cpi.com




# Device Classification


## Key Points

- Determine if your product qualifies as a medical device or IVD medical device at an early stage to understand the **applicable regulations**.
- Sufficiently clear **intended purpose** is key to meeting various aspects of the medical device regulations effectively.
- Carefully evaluate the **classification** of your devices based on its intended purpose, and associated functionality/composition etc. Seek clarification where necessary to ensure adequate consideration of regulatory requirements.

# Design Control – When?





# Medtech product development process



Average 3-7 years (US data from 2016)

## Research



## Product Development *(Design Control)*

## On-going Management *(Change Control)*

Risk management & State of the Art Evaluation

Quality Management System

- ✓ State of the art evaluation
- ✓ Product Description & Intended Purpose
- ✓ Regulatory Strategy, Product classification
- ✓ Identification of Harmonised standard & Common Spec etc.
- ✓ User and Product Requirements
- ✓ Design Verification and Validation Strategy
- ✓ Manufacturing capability
- ✓ Clinical/Performance Evaluation Planning
- ✓ Design History File (DHF)
- ✓ Device Master Record (DMR)
- ✓ Clinical Investigation
- ✓ Clinical/Performance Evaluation Finalisation
- ✓ Technical Documentation
- ✓ Regulatory Submission & Approval (12-24months )
- ✓ Product Registration
- ✓ On-going Clinical Evaluation & Post-market surveillance (PMS)
- ✓ Change Management
- ✓ Vigilance

# Public Patient involvement (PPI)



## Key points

- Involve patients, people who access services, carers, charities, community groups and others into the development of new medical devices from the early stages.

# Health Inequalities




## Key points

- Health inequalities are unfair and avoidable differences in health across the population, and between different groups within society
- Ensure you have considered the impact of your innovation on Health Inequalities



# NHS' Net Zero requirements



## Key points

- Design from the start with Net Zero in mind
- Develop a strategy and map out the environmental impact
- Understand how to assess and report carbon emissions

# Potential barriers specific to quantum sensing devices for Healthcare

- Lack of common harmonised standards to design to
- Complexity of verification and validation
- Scarcity of people with relevant expertise and skills
- Constrained manufacturing capacity

# Thank you

For more information visit [www.uk-cpi.com](http://www.uk-cpi.com)

**Tom Harvey**

Chief Technologist

[tom.harvey@uk-cpi.com](mailto:tom.harvey@uk-cpi.com)

[twitter.com/ukCPI](https://twitter.com/ukCPI) 


[facebook.com/ukCPI](https://facebook.com/ukCPI) 

[linkedin.com/company/uk-CPI](https://linkedin.com/company/uk-CPI) 

[youtube.com/ukCPI](https://youtube.com/ukCPI) 

Let's innovate together  
[www.uk-cpi.com](http://www.uk-cpi.com)







# ABHI

---

**ABHI**  
***THE VOICE OF HEALTHTECH***

---

**10<sup>th</sup> October 2024**

# DISCUSSION POINTS

---

- › ABHI – Who we are, what we do
- › Innovation
- › Building for success



**FUNCTIONS**

**STAKEHOLDER ENGAGEMENT**

**BUSINESS AREA**



**POLICY CO-ORDINATION**

**SECTOR SPECIFIC PROGRAMMES**

# ABHI'S 2024 PRIORITIES

## Key Work Areas

.....  
Strategic leadership provided by the ABHI Board,  
delivered through our network of member groups  
.....

Working across the full spectrum of HealthTech.



Single use



Capital



Surgical



Digital



Diagnostics



Robot-Assisted Surgery






# OUR EARLY DIAGNOSIS VISION







---

Early diagnosis at the  
centre of health  
management.  
Multi-modality.




# OPPORTUNITIES LIE AHEAD...

---


- ›  Decentralised diagnostics
- ›  Digital and artificial intelligence
- ›  Genomics
- ›  Productivity
- ›  Sustainability
- ›  Research

**...BUT INNOVATION UPTAKE MUST BECOME SIMPLER...**

---



# ...ESPECIALLY IN THE NHS



# BUILDING FOR SUCCESS

---








## Our survey says...

- › The UK surpasses the EU and US in having a research friendly environment and in its ability to evaluate technologies for effectiveness and value for money....but
- › ...it lags behind the EU and US in its provision of a translational research environment and its ability to adopt innovation at pace and scale.
- › The single greatest thing, by a substantial margin, that the UK Government can do to support HealthTech is deliver an effective and efficient model of international recognition within our regulatory framework.
  - IR was identified as ‘likely to considerably improve attractiveness’ by four times as many companies, compared to any initiative in any other policy area by the UK Government.
- › 1 in 3 companies are unable to meet the NHS target of Net Zero by 2045.
- › Over 30% of companies surveyed intend to expand their R&D and manufacturing investments in the UK, indicating confidence in future opportunities.

# BUILDING FOR SUCCESS

---

## Plan early to avoid pitfalls

- >  Regulatory strategy
- >  Clinical engagement
- >  Unmet needs and value proposition
- >  Sustainability
- >  Partnerships

# IT MATTERS!

**the patients association**  
Listening to patients, speaking up for change

## PATIENT EXPERIENCE OF DIAGNOSTICS

- 1 CAPACITY**  
9 out of 10 (93%) respondents want more investment in diagnostic testing capacity
- 2 LONG WAITS**  
3 out of 5 (60%) respondents would consider paying privately to avoid long waits
- 3 TESTING AT HOME**  
3 out of 4 (77%) respondents would be happy to test themselves at home
- 4 RECOVERY**  
Nearly one in five (17%) respondents said their long-term recovery was set back due to delays in getting tests or results
- 5 COMMUNICATION**  
4 out of 5 (82%) respondents want more discussion of testing options when being referred

The data come from an online survey that ran from 24th November 2023 to 2nd January 2024. The survey was completed by 1,177 respondents. Roche Diagnostics UK & Ireland funded the survey. Analysis of the survey data and development of the report and its recommendations were done by the Patients Association, without influence from Roche Diagnostics.

June 2024

## People's experiences of diagnosis

**National Voices**

*"...[the] need to make it easier for people in all parts of the country to access diagnostic services so we can end the postcode lottery for accessing a diagnosis."*

**ALZHEIMER'S RESEARCH UK FOR A CURE**    Dementia information ▾    How you can help ▾    Research ▾    About us ▾    **DONATE**

## ARE BLOOD TESTS THE FUTURE OF DEMENTIA DIAGNOSIS?

Home > Research > Online public events > Are blood tests the future of dementia diagnosis?

# MOMENTUM

---

## ABHI HealthTech **for Life**

---

### The Opportunities for **Quantum Sensing in Healthcare**

Venue: Online.

Start: Monday 25 Nov 2024 14:00

End: Monday 25 Nov 2024 15:15









© Siloton, 2024. Proprietary and Confidential



# Siloton

Personal eye scanners: seeing a healthier future

**Ben A.E. Hunt, PhD**  
Chief Commercial Officer  
+44 (0)7762 608 639  
ben.hunt@siloton.com

**Christin Henein, MD, PhD**  
Clinical Lecturer in  
Ophthalmology,  
NIHR Biomedical Research  
Centre for Ophthalmology  
Moorfields Eye Hospital and  
UCL Institute of Ophthalmology



# Health Infrastructure and Technology Translation Discussion

- The final discussion will look at adoption and any barriers you see to implementing technologies into healthcare. This can include any supporting technology needed, training, translation and any fears.


# Quantum sensing: Revolutionising Predictive Health & Early Diagnosis

Final Comments – Professor  
Melissa Mather



# **From Technology Adoption to Real-World Applications**

Quantum Sensing is Gaining  
Momentum



# **Breaking Down Silos**

Collaboration is Key to  
Unlocking Quantum's Potential



# Quantum-Enabled Diagnostics

Unmasking disease at its  
earliest stage



# **UK Quantum**

Leading the Quantum  
Revolution in Healthcare





# Quantum Healthcare

Diverse Minds, Shared Vision,  
Transforming Patient Care

